Robert Azelby - Net Worth and Insider Trading

Robert Azelby Net Worth

The estimated net worth of Robert Azelby is at least $8 Million dollars as of 2026-08-10. Robert Azelby is the EVP & Chief Commercial Officer of Juno Therapeutics Inc and owns about 89,614 shares of Juno Therapeutics Inc (JUNO) stock worth over $8 Million. Robert Azelby is also the Director of ADC Therapeutics SA and owns about 53,005 shares of ADC Therapeutics SA (ADCT) stock worth over $59,896. Details can be seen in Robert Azelby's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Robert Azelby has not made any transactions after 2024-06-17 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Robert Azelby

Are these stocks worth buying? — GuruFocus analysis for each holding

- GF

JUNO Juno Therapeutics Inc

99% of holdings · $7.8M

ADCT ADC Therapeutics SA

1% of holdings · $60K

Robert Azelby Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Robert Azelby owns 12 companies in total, including Immunomedics Inc (IMMU) , Clovis Oncology Inc (CLVSQ) , and Alder BioPharmaceuticals Inc (ALDR) among others .

Click here to see the complete history of Robert Azelby’s form 4 insider trades.

Insider Ownership Summary of Robert Azelby

Ticker	Company	Transaction Date	Type of Owner
IMMU	Immunomedics Inc	2020-06-18	director
CLVSQ	Clovis Oncology Inc	2018-10-11	director
ALDR	Alder BioPharmaceuticals Inc	2019-10-22	director & President and CEO
		2018-03-09	director
		2018-03-05	EVP & Chief Commercial Officer
		2021-08-09	director & Chief Executive Officer
		2023-04-10	director
		2024-03-01	director
		2024-01-02	director
		2025-02-20	director
		2026-03-18	director
		2026-06-19	director

Robert Azelby Latest Holdings Summary

Robert Azelby currently owns a total of 2 stocks. Among these stocks, Robert Azelby owns 89,614 shares of Juno Therapeutics Inc (JUNO) as of February 12, 2018, with a value of $8 Million and a weighting of 99.24%. Robert Azelby also owns 53,005 shares of ADC Therapeutics SA (ADCT) as of June 17, 2024, with a value of $59,896 and a weighting of 0.76%.

Latest Holdings of Robert Azelby

Ticker	Company	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
JUNO	Juno Therapeutics Inc	2018-02-12	89,614	86.96	7,792,833
ADCT	ADC Therapeutics SA	2024-06-17	53,005	1.13	59,896

Holding Weightings of Robert Azelby

Robert Azelby Form 4 Trading Tracker

According to the SEC Form 4 filings, Robert Azelby has made a total of 0 transactions in Juno Therapeutics Inc (JUNO) over the past 5 years. The most-recent trade in Juno Therapeutics Inc is the sale of 4,157 shares on February 12, 2018, which brought Robert Azelby around $355,631.

According to the SEC Form 4 filings, Robert Azelby has made a total of 1 transactions in ADC Therapeutics SA (ADCT) over the past 5 years, including 0 buys and 1 sells. The most-recent trade in ADC Therapeutics SA is the sale of 6,995 shares on June 17, 2024, which brought Robert Azelby around $20,216.

Insider Trading History of Robert Azelby

* The information on this page (including Insider Trading Shares, Share Changes, Cost, etc.) is sourced exclusively from Form 4 filings and does not incorporate any data from 13F or 13D/G filings. As a result, it may differ from the values shown on the Guru page.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Robert Azelby Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Get the full picture on these stocks

See GF Score, valuation, financials, and warning signs for every stock Robert Azelby owns.

- JUNO - ADCT

View JUNO Analysis

Robert Azelby Ownership Network

Ownership Network List of Robert Azelby

No Data

Ownership Network Relation of Robert Azelby

Robert Azelby Owned Company Details

What does Immunomedics Inc do?

Who are the key executives at Immunomedics Inc?

Robert Azelby is the director of Immunomedics Inc. Other key executives at Immunomedics Inc include director & 10 percent owner & other: See Remarks Avoro Capital Advisors Llc , director & 10 percent owner & other: See Remarks Behzad Aghazadeh , and director & President and CEO Harout Semerjian .

Immunomedics Inc (IMMU) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Immunomedics Inc (IMMU) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Immunomedics Inc (IMMU) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Immunomedics Inc (IMMU)'s detailed insider trading history can be found in Insider Trading Tracker table.

Immunomedics Inc Insider Transactions

No Available Data

What does Clovis Oncology Inc do?

Who are the key executives at Clovis Oncology Inc?

Robert Azelby is the director of Clovis Oncology Inc. Other key executives at Clovis Oncology Inc include See Remarks Thomas C. Harding , See Remarks Gillian C Ivers-read , and See remarks Lindsey Rolfe .

Clovis Oncology Inc (CLVSQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Clovis Oncology Inc (CLVSQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Clovis Oncology Inc (CLVSQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Clovis Oncology Inc (CLVSQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Clovis Oncology Inc Insider Transactions

No Available Data

What does Alder BioPharmaceuticals Inc do?

Who are the key executives at Alder BioPharmaceuticals Inc?

Robert Azelby is the director & President and CEO of Alder BioPharmaceuticals Inc. Other key executives at Alder BioPharmaceuticals Inc include 10 percent owner H Lundbeck A S , Chief Medical Officer Paul Streck , and Chief Financial Officer Carlos Campoy .

Alder BioPharmaceuticals Inc (ALDR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Alder BioPharmaceuticals Inc (ALDR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Alder BioPharmaceuticals Inc (ALDR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Alder BioPharmaceuticals Inc (ALDR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Alder BioPharmaceuticals Inc Insider Transactions

No Available Data

What does Cascadian Therapeutics Inc do?

Who are the key executives at Cascadian Therapeutics Inc?

Robert Azelby is the director of Cascadian Therapeutics Inc. Other key executives at Cascadian Therapeutics Inc include 10 percent owner Nea Partners 15, L.p. , 10 percent owner Jon Sakoda , and 10 percent owner Florence Anthony A. Jr. .

Cascadian Therapeutics Inc (CASC) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Cascadian Therapeutics Inc (CASC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cascadian Therapeutics Inc (CASC) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Cascadian Therapeutics Inc (CASC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cascadian Therapeutics Inc Insider Transactions

No Available Data

What does Juno Therapeutics Inc do?

Who are the key executives at Juno Therapeutics Inc?

Robert Azelby is the EVP & Chief Commercial Officer of Juno Therapeutics Inc. Other key executives at Juno Therapeutics Inc include director & CEO & President Hans Edgar Bishop , 10 percent owner Celgene Corp /de/ , and 10 percent owner Celgene Switzerland Llc .

Juno Therapeutics Inc (JUNO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Juno Therapeutics Inc (JUNO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Juno Therapeutics Inc (JUNO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Juno Therapeutics Inc (JUNO)'s detailed insider trading history can be found in Insider Trading Tracker table.

Juno Therapeutics Inc Insider Transactions

No Available Data

What does Climb Bio Inc do?

Who are the key executives at Climb Bio Inc?

Robert Azelby is the director & Chief Executive Officer of Climb Bio Inc. Other key executives at Climb Bio Inc include director & President and CEO Aoife Brennan , director & 10 percent owner Ra Capital Healthcare Fund Lp , and Chief Financial Officer Susan Altschuller .

Climb Bio Inc (CLYM) Insider Trades Summary

Over the past 18 months, Robert Azelby made no insider transaction in Climb Bio Inc (CLYM). Other recent insider transactions involving Climb Bio Inc (CLYM) include a net purchase of 321,672 shares made by Ra Capital Healthcare Fund Lp , a net sale of 150,000 shares made by Stephen Basil Thomas , and a net sale of 51,520 shares made by Aoife Brennan .

In summary, during the past 3 months, insiders sold 30,902 shares of Climb Bio Inc (CLYM) in total and bought 0 shares, with a net sale of 30,902 shares. During the past 18 months, 203,961 shares of Climb Bio Inc (CLYM) were sold and 321,672 shares were bought by its insiders, resulting in a net purchase of 117,711 shares.

Climb Bio Inc (CLYM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Climb Bio Inc Insider Transactions

No Available Data

What does Chinook Therapeutics Inc do?

Who are the key executives at Chinook Therapeutics Inc?

Robert Azelby is the director of Chinook Therapeutics Inc. Other key executives at Chinook Therapeutics Inc include Head of Renal Discovery Andrew James King , director & President & CEO Eric Dobmeier , and director & 10 percent owner Davis Jerel .

Chinook Therapeutics Inc (KDNY) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Chinook Therapeutics Inc (KDNY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Chinook Therapeutics Inc (KDNY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Chinook Therapeutics Inc (KDNY)'s detailed insider trading history can be found in Insider Trading Tracker table.

Chinook Therapeutics Inc Insider Transactions

No Available Data

What does Cardinal Health Inc do?

Who are the key executives at Cardinal Health Inc?

Robert Azelby is the director of Cardinal Health Inc. Other key executives at Cardinal Health Inc include Chief Information Officer Michelle D. Greene , Chief Financial Officer Aaron E Alt , and CHRO Valerie Christine Pitteroff .

Cardinal Health Inc (CAH) Insider Trades Summary

Over the past 18 months, Robert Azelby made no insider transaction in Cardinal Health Inc (CAH). Other recent insider transactions involving Cardinal Health Inc (CAH) include a net sale of 143,606 shares made by Jason M. Hollar , a net sale of 50,571 shares made by Aaron E Alt , and a net sale of 16,246 shares made by Michelle D. Greene .

In summary, during the past 3 months, insiders sold 0 shares of Cardinal Health Inc (CAH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 350,360 shares of Cardinal Health Inc (CAH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 350,360 shares.

Cardinal Health Inc (CAH)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cardinal Health Inc Insider Transactions

No Available Data

What does ADC Therapeutics SA do?

Who are the key executives at ADC Therapeutics SA?

Robert Azelby is the director of ADC Therapeutics SA. Other key executives at ADC Therapeutics SA include 10 percent owner Redmile Group, Llc , Chief Legal Officer Peter J Graham , and 10 percent owner Jeremy Green .

ADC Therapeutics SA (ADCT) Insider Trades Summary

Over the past 18 months, Robert Azelby made no insider transaction in ADC Therapeutics SA (ADCT). Other recent insider transactions involving ADC Therapeutics SA (ADCT) include a net sale of 5,880,415 shares made by Redmile Group, Llc ,

In summary, during the past 3 months, insiders sold 0 shares of ADC Therapeutics SA (ADCT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 5,880,415 shares of ADC Therapeutics SA (ADCT) were sold and 0 shares were bought by its insiders, resulting in a net sale of 5,880,415 shares.

ADC Therapeutics SA (ADCT)'s detailed insider trading history can be found in Insider Trading Tracker table.

ADC Therapeutics SA Insider Transactions

No Available Data

What does Terns Pharmaceuticals Inc do?

Who are the key executives at Terns Pharmaceuticals Inc?

Robert Azelby is the director of Terns Pharmaceuticals Inc. Other key executives at Terns Pharmaceuticals Inc include Chief Medical Officer Emil Kuriakose , director & Chief Executive Officer Amy L. Burroughs , and Chief Financial Officer Andrew Gengos .

Terns Pharmaceuticals Inc (TERN) Insider Trades Summary

Over the past 18 months, Robert Azelby made no insider transaction in Terns Pharmaceuticals Inc (TERN). Other recent insider transactions involving Terns Pharmaceuticals Inc (TERN) include a net sale of 145,940 shares made by Amy L. Burroughs , a net sale of 4,846 shares made by Emil Kuriakose , and a net purchase of 25,000 shares made by Andrew Gengos .

In summary, during the past 3 months, insiders sold 0 shares of Terns Pharmaceuticals Inc (TERN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 198,620 shares of Terns Pharmaceuticals Inc (TERN) were sold and 48,314 shares were bought by its insiders, resulting in a net sale of 150,306 shares.

Terns Pharmaceuticals Inc (TERN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Terns Pharmaceuticals Inc Insider Transactions

No Available Data

What does Autolus Therapeutics PLC do?

Who are the key executives at Autolus Therapeutics PLC?

Robert Azelby is the director of Autolus Therapeutics PLC. Other key executives at Autolus Therapeutics PLC include U.S. CCO & Country Gen Manager Cintia Piccina , Chief Financial Officer Robert Dolski , and director & Chief Executive Officer Christian Itin .

Autolus Therapeutics PLC (AUTL) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Autolus Therapeutics PLC (AUTL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Autolus Therapeutics PLC (AUTL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Autolus Therapeutics PLC (AUTL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Autolus Therapeutics PLC Insider Transactions

No Available Data

What does Tango Therapeutics Inc do?

Who are the key executives at Tango Therapeutics Inc?

Robert Azelby is the director of Tango Therapeutics Inc. Other key executives at Tango Therapeutics Inc include See Remarks Adam Crystal , Principal Accounting Officer Jessica Newcomb , and Chief Financial Officer Matthew Gall .

Tango Therapeutics Inc (TNGX) Insider Trades Summary

Over the past 18 months, Robert Azelby made no insider transaction in Tango Therapeutics Inc (TNGX). Other recent insider transactions involving Tango Therapeutics Inc (TNGX) include a net sale of 278,508 shares made by Adam Crystal , a net sale of 3,472,501 shares made by Third Rock Ventures Iv, L.p. , and a net sale of 30,519 shares made by Barbara Weber .

In summary, during the past 3 months, insiders sold 81,000 shares of Tango Therapeutics Inc (TNGX) in total and bought 0 shares, with a net sale of 81,000 shares. During the past 18 months, 3,791,845 shares of Tango Therapeutics Inc (TNGX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 3,791,845 shares.

Tango Therapeutics Inc (TNGX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Tango Therapeutics Inc Insider Transactions

No Available Data

Robert Azelby Mailing Address

Above is the net worth, insider trading, and ownership report for Robert Azelby. Based on the public information released on the U.S. Securities and Exchange Commission (SEC) website, Robert Azelby's mailing address is: Dublin Oh 43017.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.